EyePoint Pharmaceuticals (NASDAQ: EYPT) reported Q2 EPS of ($0.58), $0.04 worse than the analyst estimate of ($0.54). Revenue for the quarter came in at $9.48 million versus the consensus estimate of $9.64 million.

For earnings history and earnings-related data on EyePoint Pharmaceuticals (EYPT) click here.